Imaging

FFRCT Slashes PAD + CAD Mortality

A study in the Journal of Vascular Surgery revealed that adding FFRCT assessments to patient workups prior to peripheral artery disease surgeries has a massive impact on coronary artery disease detection, treatments, and long-term outcomes.

  • Over 230 million people globally suffer from PAD, and up to 80% of them have concurrent coronary artery disease, but many are unaware of their CAD status.

The researchers randomized 522 surgical PAD patients who hadn’t been diagnosed with CAD to either undergo HeartFlow FFRCT testing or receive standard preoperative cardiac evaluations.

FFRCT analysis revealed high rates of asymptomatic lesion-specific coronary ischemia (65%), severe ischemia (52%), multivessel ischemia (36%), and left main ischemia (8%). 

  • Meanwhile, the usual care group’s coronary ischemia statuses remained unknown (because they didn’t test for it).

The two groups then received their vascular surgery as planned, and they had no differences in 30-day mortality or post-procedure care.

By month three after vascular surgery, 103 of the FFRCT patients underwent elective ischemia-targeted coronary revascularization. 

  • Meanwhile, zero members of the usual care group had elective coronary revascularizations (because their ischemia wasn’t identified).

So far, we’ve shown that more CAD testing leads to more CAD treatments, but the study’s five-year follow-up data also shows that these added tests and treatments led to far better outcomes. The FFRCT treatment group had much lower…

  • All-cause mortality rates (16% vs. 36%)
  • Cardiovascular mortality rates (4% vs. 21%)
  • Myocardial infarction rates (4% vs. 24%)
  • MACE rates (27% vs. 47%)

In other words, the patients who received FFRCTs were 63% less likely to die during the five years following their PAD surgeries, 89% less likely to die from cardiovascular causes, and 87% less likely to have a heart attack.

The Takeaway

Although PAD patients’ high CAD risks are already well established, this study provides perhaps the strongest evidence yet supporting the benefits of using FFRCT to test PAD patients and guide their CAD treatment decisions.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Surgeries & Interventions June 23, 2025

Edwards’ Evoque Might Have More Adverse Events Than Previously Known June 23, 2025

Over a year after becoming the first FDA-approved transcatheter tricuspid valve replacement system, a new JACC study suggests Edwards Lifesciences’ Evoque TTVR system might have some risks that regulators hadn’t previously considered. Searching for more answers about Evoque’s real world risks, researchers pulled data from the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database […]

Cardiology Business June 19, 2025

Lilly Buys Verve, Bringing Gene Editing Mainstream June 19, 2025

Gene editing for heart disease just got a major boost as Eli Lilly acquired Verve Therapeutics and its one-dose cholesterol drugs for up to $1.3B, marking a new path for Verve’s therapies to go mainstream. Part of the acquisition likely stems from Verve’s recent impressive trial results for its PCSK9-blocking treatment, VERVE-102, which lowered LDL-C […]

Cardiac Imaging June 19, 2025

New AI-driven Tool Aids in Mitral Valve Assessment June 19, 2025

By: Jimmy Su, Ph.D. Principal Scientist, Cardiovascular Ultrasound, Philips A new tool, Automated 3D Color Flow Quantification (3D Auto CFQ), removes the reliance on assumptions when quantifying mitral regurgitation and replaces it with a reliable and robust, AI-driven method that delivers precise measurement of mitral valve regurgitant volume (RVol) regardless of orifice shape and size. Eliminating assumptions: Quantification […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!